The purpose of this study is to collect medical informations and samples from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms.
The purpose of this study is to collect medical informations and samples (blood, bone marrow and/or lymph node) from refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax treatment, in order to evaluate the frequency of resistance mechanisms (BCL2 mutations, over-expression of other members of the BCL2 protein family and energy metabolism changes).
Study Type
OBSERVATIONAL
Enrollment
50
CHU d'Amiens
Amiens, France
NOT_YET_RECRUITINGCHU de Besançon
Besançon, France
NOT_YET_RECRUITINGFrequency measurement of BCL2 gene mutations
Frequency measurement of BCL2 gene mutations in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Time frame: immediately after the chronic lymphocytic leukemia progression
Frequency measurement of 1q amplification
Frequency measurement of 1q amplification in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Time frame: immediately after the chronic lymphocytic leukemia progression
Differential expression of candidate transcripts and proteins
Differential expression of candidate transcripts and proteins (BCL2 protein family, AMP signaling pathway, energy metabolism) in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Time frame: immediately after the chronic lymphocytic leukemia progression
Correlation of resistance mechanisms with clinical staging
Correlation of resistance mechanisms (BCL2 mutation and 1q amplification) with clinical staging, in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Time frame: immediately after the chronic lymphocytic leukemia progression
Correlation of resistance mechanisms with genomic chronic lymphocytic leukemia features
Correlation of resistance mechanisms (BCL2 mutation and 1q amplification) with genomic chronic lymphocytic leukemia features, in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Time frame: immediately after the chronic lymphocytic leukemia progression
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Hopital AVICENNE
Bobigny, France
CHU clermont-ferrand
Clermont-Ferrand, France
NOT_YET_RECRUITINGCHU de Clermont Ferrand
Clermont-Ferrand, France
NOT_YET_RECRUITINGCHU Grenoble
Grenoble, France
NOT_YET_RECRUITINGCHRU de Lille
Lille, France
NOT_YET_RECRUITINGCentre LEON BERARD
Lyon, France
NOT_YET_RECRUITINGCHU de Montpellier
Montpellier, France
NOT_YET_RECRUITINGCHU Nancy
Nancy, France
NOT_YET_RECRUITING...and 4 more locations
Progression Free Survival according to resistance mechanisms
Progression Free Survival according to resistance mechanisms (BCL2 mutation and 1q amplification), in a cohort of refractory and/or relapsed chronic lymphocytic leukemia during or after venetoclax therapy
Time frame: immediately after the chronic lymphocytic leukemia progression